Preventing Respiratory Syncytial Virus in Infants

• 2024

  Log in to bookmark this resource.

  Log in
• Samantha Moe; Sam Wong; Michael Kolber
PMID: 39406437DOI: https://dx.doi.org/10.46747/cfp.7010e155

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This one-page article outlines how monoclonal antibodies can help prevent respiratory syncytial virus (RSV) in infants. Palivizumab, given in 4 to 5 doses during RSV season, reduces hospital visits for high-risk infants. Nirsevimab, a single dose, lowers RSV hospitalizations in both healthy premature and term infants. Side effects are similar to placebo treatments. The National Advisory Committee on Immunization recommends nirsevimab for certain infant groups at risk of severe RSV disease and considers it more cost-effective than palivizumab. In Canada, most RSV cases happen between November and April each year.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Canada; Heart Defects, Congenital; Hospitalization; Infant, Newborn; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Premature Birth; Lung Diseases, Interstitial; Palivizumab; Antibodies, Monoclonal, Humanized

Institutions: University of Alberta; The College of Family Physicians of Canada

---

More like this

Ethical Obligations Regarding Short-Term Global Health Clinical Experiences: An American College of Physicians Position Paper 2018 · Johns Hopkins University, National Center for Ethics in Health Care, U.S. Department of Veterans Affairs, University of California –San Diego School of Medicine, University of California, San Diego, Virginia Mason Medical Center Children and Adolescents with Disabilities and Exposure to Disasters, Terrorism, and the COVID-19 Pandemic: A Scoping Review 2021 · Albert Einstein College of Medicine, Children's Hospital at Montefiore Paediatric Emergency Triage, Assessment and Treatment (ETAT) – Preparedness for Implementation at Primary Care Facilities in Malawi 2021 · Karolinska Institutet, University of Malawi, University College London, Malawi Epidemiology and Intervention Research Unit, Parent and Child Health Initiative Trust, Liverpool School of Tropical Medicine

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---